Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study

Osteoporosis International

Volumn 15, Issue 2, 2004, Pages 168-174

  Nielsen, Therese F ^a   Ravn, Pernille ^a   Bagger, Yu Z ^a   Warming, Lise ^a   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

BMDU; Bone markers; Intranasal estradiol; Osteoporosis; Postmenopausal women

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; ESTROGEN; OSTEOCALCIN; PLACEBO; PROGESTERONE; S 21400;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG PULSE THERAPY; DRUG TOLERABILITY; ESTROGEN THERAPY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HEADACHE; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINORRHEA; SIDE EFFECT; SKIN MANIFESTATION; SNEEZING; VAGINA DISCHARGE;

ADMINISTRATION, INTRANASAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 1342332564     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1535-8     Document Type: Article

References (20)

1. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841-1850
2. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
3. Christiansen C, Lindsay R (1990) Estrogens, bone loss and preservation. Osteoporos Int 1:7-13
4. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
5. Gail A, Greendale MD, Espeland M et al. (2002) Bone mass response to discontinuation of long term hormone replacement therapy. Arch Int Med 162:665-672
6. Johnell O, Kanis JA, Oden A et al. (2001) Targeting of hormone replacement therapy immediately after menopause. Bone 28:440-445
7. Studd J, Pornel B, Marton I et al. (1999) Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet 353:1574-1578
8. Devissaguet JP, Brion N, Lhote O, Deloffre P (1999) Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (intranasal oestradiol) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 24:265-271
9. Lopes P, Merkus HM, Nauman J, Bruschi F, Foidart JM, Calaf J (2000) Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 96:906-912
10. Mattsson LA, Christiansen C, Colau JC et al. (2000) Clinical equivalence of intranasal and oral 17 beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 182:545-552
11. Rozenbaum H, Chevallier O, Moyal M et al. (2002) Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Climacteric 5:249-258
12. Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389-1396
13. Ettinger B, Genant HK, Steiger P, Madvig P (1992) Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 166:479-488
14. Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP et al. (1999) for The International Study Group. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. Osteoporos Int 9:358-366
15. Delmas PD, Bjarnason NH, Mitlak BH et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
16. Gallagher JC, Baylink DJ, Freeman R, McClung M (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86:4717-4726
17. Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate C (1999) A dose-ranging trial of a matrix trandermal 17 beta-estradiol in the prevention of bone loss in early menopausal women. Bone 24:517-523
18. Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C. Delmas PD (1999) Effects of intranasal beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 84:2390-2391
19. Delmas PD, Hardy P, Garnero P, Dain M (2000) Monitoring individual response to hormone replacement therapy with bone markers. Bone 26:553-560
20. Gompel A, Bergeron C, Jondet M, Dhont M, Van der Mooren MJ, Toth KS et al. (2000) Endometrial safety and tolerability of Aerodiol® (intranasal estradiol) for 1 year. Maturitas 36:209-215